H
301246
vs
S
Shanghai Composite
Over the past 12 months, Hubei Hongyuan Pharmaceutical Technology Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +45% compared to the Shanghai Composite's +23% growth.
Stocks Performance
301246 vs Shanghai Composite
Performance Gap
301246 vs Shanghai Composite
Performance By Year
301246 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hubei Hongyuan Pharmaceutical Technology Co Ltd
Glance View
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. principally engages in the research, development, production, and sale of organic chemical raw materials, pharmaceutical intermediates, raw materials, and pharmaceutical preparations. The company is headquartered in Huanggang, Hubei and currently employs 2,164 full-time employees. The company went IPO on 2023-03-20. The firm is also engaged in the production of lithium hexafluorophosphate, one of the main materials for lithium battery electrolyte. The firm's main products are divided into organic chemical raw materials such as glyoxal in the ethylene glycol reaction chain, pharmaceutical intermediates such as glyoxylic acid, 2-methyl-5-nitroimidazole and other products, and raw materials such as metronidazole; Pharmaceutical intermediates guanine, diacetylguanine and other products in the reaction chain of methyl cyanoacetate and guanidine hydrochloride. The firm distributes its products in the domestic market and overseas markets.
